Spraying tranexamic acid and sucralfate powders to stop bleeding from upper GI tumors
Official title: Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Tumor Bleeding: A Randomized Controlled Trial
Run by National Cheng-Kung University Hospital · NCT07540026 · Data updated 2026-11-12
Doctors will try spraying tranexamic acid and sucralfate powders during endoscopy to stop bleeding in adults with upper gastrointestinal tumor bleeding.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | National Cheng-Kung University Hospital Academic / other |
| Locations | 1 site (Tainan, Not Required For This Country) |
| Status | Recruiting |
| Started | May 1, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | April 20, 2026 |
| Trial ID | NCT07540026 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older undergoing endoscopy for upper GI tumor bleeding who need endoscopic hemostasis and have no contraindication to tranexamic acid or sucralfate are eligible.
✕Probably not a fit
Patients who do not require endoscopic hemostasis, are allergic to the study drugs, are pregnant, or have hollow organ perforation are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized interventional trial enrolls adults with upper GI tumor bleeding who require endoscopic hemostasis and randomizes them to receive endoscopic application of drug powders versus standard hemostatic care. The active treatment combines 3 g of sucralfate powder and 1.5 g of tranexamic acid powder sprayed onto the bleeding tumor surface during endoscopy. Primary outcomes include immediate hemostasis and subsequent rebleeding rates, with follow-up to capture recurrence and need for further interventions. The trial is conducted at National Cheng Kung University Hospital in Tainan, Taiwan as a single-center study.
Why it matters
Potential benefit: If successful, this approach could improve immediate bleeding control and lower rebleeding rates, reducing transfusions and the need for additional procedures.
How similar studies have gone: Hemostatic powder spraying has improved control and reduced recurrence in trials for peptic ulcers and post-polypectomy bleeding, but applying tranexamic acid plus sucralfate powders specifically for tumor bleeding is a relatively new approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients aged ≥ 18 years who accept endoscopy for upper GI tumor bleeding Exclusion Criteria: * patients with no need for endoscopic hemostasis, allergy to sucralfate, tranexamic acid, pregnancy, and patients with hollow organ perforation
Where it's running
-
National Cheng Kung University Hospital
Tainan, Not Required For This Country, Taiwan Recruiting
Study contacts
- Study coordinator: Hsueh-Chien Chiang, MD
- Email: scion456scion@gmail.com
- Phone: 8862353535
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bleeding rates in patients on blood thinners undergoing endoscopy
This study looks at how often patients on blood thinners bleed during endoscopy procedures like EGD and colonoscopy to see if it's safe for them to have these tests.
-
Identifying risk factors and outcomes for patients needing acute surgical care
This study looks at patients who needed emergency surgery to see what factors might lead to complications or death, helping to improve future treatments and care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.